New Delhi, Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to market the generic version of Dapsone Gel, used to treat acne.
The final approval by the US Food and Drug Administration (USFDA) is for Dapsone Gel in 7.5 per cent strength, Zydus Lifesciences said in a regulatory filing.
It said Dapsone gel is used to treat acne and will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedabad.
Zydu Lifesciences said annual sales in the US for Dapsone Gel, 7.5 percent were US$35.8 million, citing IQVIA MAT March 2024 data.
The final approval by the US Food and Drug Administration (USFDA) is for Dapsone Gel in 7.5 per cent strength, Zydus Lifesciences said in a regulatory filing.
It said Dapsone gel is used to treat acne and will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedabad.
Zydu Lifesciences said annual sales in the US for Dapsone Gel, 7.5 percent were US$35.8 million, citing IQVIA MAT March 2024 data.
